Halozyme Therapeutics, Inc. (NASDAQ:HALO) Weekly Ratings as of Jun 27, 2018

June 27, 2018 - By Noel Courtney

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Corporate Logo
During Q1 2018 the big money sentiment decreased to 1.51. That’s change of 0.15, from 2017Q4’s 1.66. 16 investors sold all, 49 reduced holdings as Halozyme Therapeutics, Inc. ratio dropped. 56 rose positions while 42 funds amassed positions. Funds hold 119.54 million shares thus 1.04% more from 2017Q4’s 118.31 million shares.
Cubist Systematic Strategies Ltd Liability holds 13,212 shs or 0.02% of its capital. Utd Automobile Association accumulated 19,906 shs. Paloma Ptnrs Management holds 0.01% or 45,130 shs. 764,139 were accumulated by Manufacturers Life Commerce The. Mackay Shields Lc has invested 0.01% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Gsa Capital Prtnrs Llp owns 103,100 shs. Price T Rowe Assoc Incorporated Md accumulated 45,645 shs. Jacobs Levy Equity Mngmt holds 0.08% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 254,740 shs. Deutsche Commercial Bank Ag reported 873,511 shs or 0.01% of all its holdings. Daiwa Securities Grp, Japan-based fund reported 787 shs. Hbk Investments Ltd Partnership has 0.02% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). State Of Wisconsin Inv Board invested in 117,900 shs. Doheny Asset Mgmt Ca reported 1.68% stake. The Bermuda-based Btg Pactual Glob Asset Ltd has invested 0.18% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Creative Planning has 84,792 shs for 0.01% of their capital.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

In total 6 analysts cover Halozyme (NASDAQ:HALO). “Buy” rating has 3, “Sell” are 1, while 2 are “Hold”. 50% are bullish. 8 are the (NASDAQ:HALO)’s analyst reports since January 17, 2018 according to StockzIntelligence Inc. The stock rating was maintained by JP Morgan with “Overweight” on Wednesday, February 21. In Wednesday, February 21 report Canaccord Genuity maintained the stock with “Buy” rating. On Friday, May 11 the stock has “Underweight” rating by Barclays Capital. In Thursday, February 22 report BMO Capital Markets maintained the stock with “Market Perform” rating. On Monday, May 14 Canaccord Genuity maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating. Canaccord Genuity has “Buy” rating and $2100 target. On Wednesday, January 24 Deutsche Bank maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating. Deutsche Bank has “Buy” rating and $21.0 target. Listed here are Halozyme Therapeutics, Inc. (NASDAQ:HALO) PTs and latest ratings.

14/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0000 Maintain
11/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $19 Downgrade
22/02/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $18 New Target: $19 Maintain
21/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0 Maintain
21/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $19 New Target: $22 Maintain
24/01/2018 Broker: Deutsche Bank Rating: Buy New Target: $21.0 Maintain
24/01/2018 Broker: Goldman Sachs Rating: Neutral New Target: $20 Initiates Coverage On
17/01/2018 Broker: BMO Capital Markets Rating: Hold New Target: $18.0

HALO is touching $17.95 during the last trading session, after decreased 0.22%.Currently Halozyme Therapeutics, Inc. is uptrending after 46.03% change in last June 27, 2017. HALO has also 23,747 shares volume. HALO outperformed by 33.46% the S&P 500.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally.The company has $2.57 billion market cap. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.The P/E ratio is 37.63. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

There’s a substantial Halozyme Therapeutics, Inc. (NASDAQ:HALO) news brought out by Globenewswire.com. It’s a report titled: “Report: Exploring Fundamental Drivers Behind Virtu Financial, Littelfuse, Gogo, Brookfield Asset Management, Protalix …” on June 13, 2018.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: